What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Acidification solvent · process auxiliary
Vialdyne primary owner
This Vialdyne page is the primary SEO owner for buyers evaluating Acetic Acid (Glacial / Concentrated Solvent) through a pharmacy QA, clinic procurement, or regulated-sourcing workflow. It should answer whether the buyer can request a batch COA, release-test scope, destination-market review, and add-on documentation before moving into pricing or repeat inventory planning.
Overview
Concentrated, or glacial, acetic acid is catalogued here as a process-auxiliary solvent for compounding pharmacy and research workflows that need to prepare acidic-pH peptide reconstitution diluents in-house at custom concentrations. The catalogue's pre-mixed 0.6% Acetic Acid Water diluent handles the most common acidic-pH reconstitution case, but some peptide-stability profiles call for alternative acetic-acid concentrations (0.1%, 0.3%, and 1.0% are the typical custom dilutions), and the upstream starting material for in-house preparation of those is concentrated anhydrous acetic acid at ≥99.7% purity. Glacial refers to the anhydrous, concentrated form that crystallises below 16.6 C. Vialdyne stocks glacial acetic acid as a ≥99.0% HPLC-purity reagent in 10 ml sealed packaging. This SKU is catalogued as a process auxiliary rather than a peptide API, so the analytical workflow follows the standard solvent-grade specification, GC, water content, and residual impurities, rather than peptide-style HPLC plus mass spec. Pharmacies preparing in-house diluents should follow the relevant local pharmacopoeia requirements for solvent quality and must terminally sterilise the resulting diluent before any injectable-grade use, the parent solvent is not itself terminally sterile.
Applications & buyer fit
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Ratio target, the analytical method to verify it, stability protocol, and packaging are defined in the OEM brief before the first commercial run.
Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.
Specifications
Certificate of Analysis
Published released-batch COAs for Acetic Acid (Glacial / Concentrated Solvent), every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
VerifiedRequest full COA →Acetic Acid (Glacial / Concentrated Solvent)
VD260428-AA003
VerifiedRequest full COA →Acetic Acid (Glacial / Concentrated Solvent)
VD260428-AA002
Regulatory note
Sold as a multi-peptide active for research and for OEM-formulated finished products under the receiving brand's regulatory framework. Blend composition, finished-product safety, labeling claims, and notification responsibilities remain with the brand owner. Component-level analytical data is supplied for every batch.
Frequently asked questions
The concentrated material is a starting solvent, so the pharmacy carries responsibility for the finished dilution. Establish the target strength (commonly a dilute acidic water used for solubility-limited peptides), calculate the volume of concentrate against purified or sterile water, and prepare in a validated, corrosion-compatible vessel. Because it is an in-house preparation for an injectable pathway, define acceptance controls such as final pH and a sterilizing filtration step, and record the concentrate lot so identity traces through to the compounded diluent. Do not treat a household or food-grade acid as interchangeable; the impurity profile is not qualified for this use.
Even as a process auxiliary rather than an API, the concentrate should arrive with a certificate stating assay (the ≥99% anhydrous grade), water content, and residue or heavy-metal limits appropriate to a material entering an injectable preparation. Confirm the grade is pharmaceutical or higher rather than technical, capture the lot number and expiry, and file the safety data sheet alongside your qualification record. Because you are diluting it into a product that reaches patients, the impurity ceiling on the incoming solvent effectively sets the floor for what your finished acidic diluent can achieve, so verify those limits before first use.
